Keyphrases
Mouse Model
100%
Phosphoinositide 3-kinase (PI3K)
100%
ERK Pathway
100%
Neuroprotective Properties
100%
Parkinson's Disease Model
100%
Icariin
100%
Striatum
50%
Parkinson's Disease
30%
PD98059
30%
LY294002
30%
Tyrosine Hydroxylase
30%
Dopamine Level
30%
Substantial Nigra
30%
Pars Compacta
30%
Protein Expression
20%
B-cell Lymphoma 2 (Bcl-2)
20%
Neuroprotective Effect
20%
Dopaminergic Neurons
20%
MES23.5 Cells
20%
Possible Mechanisms
10%
Active Ingredients
10%
Western Blot
10%
Caspase-3
10%
Mitogen-activated Protein Kinase
10%
Co-treatment
10%
Akt Phosphorylation
10%
Immunohistochemistry
10%
Ovariectomized
10%
Phosphatidylinositol 3-kinase Inhibitor
10%
ERK Phosphorylation
10%
MEK-ERK Pathway
10%
Caspase-3 Protein
10%
Epimedium Sagittatum
10%
MEK Inhibitor (MEKi)
10%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Icariin
100%
Phosphatidylinositol 3 Kinase
100%
1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine
100%
Parkinson's Disease
100%
Neuroprotective Agent
100%
Mitochondrial Permeability Transition Pore
100%
Protein Kinase B
100%
2 Morpholino 8 Phenylchromone
30%
Tyrosine 3 Monooxygenase
30%
Dopamine Receptor Stimulating Agent
30%
2 (2 Amino 3 Methoxyphenyl)chromone
30%
Caspase 3
20%
Western Blot
10%
High Performance Liquid Chromatography
10%
Phosphatidylinositol 3 Kinase Inhibitor
10%
Mitogen Activated Protein Kinase Kinase Inhibitor
10%
Mitogen Activated Protein Kinase Kinase
10%
Epimedium
10%
Neuroscience
Parkinson's Disease
100%
Neuroprotective Agent
100%
MPTP
100%
Protein Kinase B
100%
Phosphoinositide 3-Kinase
100%
Icariin
100%
Striatum
50%
Tyrosine Hydroxylase
30%
LY294002
30%
Bcl-2
20%
Caspase 3
20%
Dopaminergic Neuron
20%
Protein Expression
20%
Dopaminergic
10%
Cell Signaling
10%
Western Blot
10%
Mitogen-Activated Protein Kinase Kinase
10%
Immunohistochemistry
10%
MEK Inhibitor
10%
Phosphoinositide 3-Kinase Inhibitor
10%